Use of traditional medicine for hypertension, diabetes and hypercholesterolaemia measured in 71 surveys.

Sulola MA, Sibai AM, Damasceno A, Issanov A, Sarria-Santamera A, Orazumbekova B, Norov B, Bicaba B, Houehanou C, Guwatudde D, Kagaruki GB, Gathecha G, Jorgensen JA, Mwangi KJ, Agoudavi K, Sturua L, Mayige MT, Gurung M, Hwalla N, Lunet N, Mwalim O, McClure RW, Quesnel-Crooks S, Bahendeka S, Atun R, Bärnighausen T, Davies J, Flood D, Geldsetzer P, Jaacks L, Manne-Goehler J, Theilmann M, Vollmer S, Marcus ME.
Bull World Health Organ
http://www.ncbi.nlm.nih.gov/pubmed/41180269

PRIMARY-AI: outcomes-based standards to safeguard primary care in the AI era.

Zeng D, Car LT, Khunti K, Liu Y, Bärnighausen T, Chavannes NH, Keane PA, Kunz H, Xue L, Sung JJY, Tham YC, Righetto L, Sarker R, Wong SYS, Boudreau D, Dai Q, Jia W, Liu Y, Shen D, Liu J, Shen W, Ji JS, Wang Z, Wang Z, Wang H, Tang S, Pei C, Jiang Z, Zou Z, Qin Y, Li H, Wang Y, Gunasekeran DV, Wong S, Xu D, Urbanowicz R, Laranjo L, Neves AL, Liu N, He Y, Le PV, Bressler N, Atun R, Klonoff DC, Sheng B, Shah N, Car J, Wong TY.
Nat Med
http://www.ncbi.nlm.nih.gov/pubmed/41673309

GLP-1 receptor agonists for obesity: eligibility across 99 countries.

Yoo SGK, Teufel F, Theilmann M, Si Y, Toure EA, Aryal K, Bärnighausen T, Bait A, Barreto M, Bovet P, Brant LCC, Cuschieri S, Damasceno A, Farzadfar F, Fawwad A, Geldsetzer P, Hambleton IR, Houehanou C, Howitt C, J Rgensen J, González-Rivas JP, Labadarios D, Marcus M, Martins J, Mwalim O, Nieto-Martínez R, Odili AN, Orazumbekova B, Perman G, Quesnel-Crooks S, Moghaddam SS, Sewpal R, Sousa-Uva M, Sulola MA, Venkataraman K, Vollmer S, Xueling S, Atun R, Banegas JR, Franco JVA, Arnott C, Chandiwana N, Huffman MD, Davies J, Ali MK, Flood D, Manne-Goehler J.
Lancet Diabetes Endocrinol
http://www.ncbi.nlm.nih.gov/pubmed/41519598